150 related articles for article (PubMed ID: 34325089)
1. Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals.
Chigoho DM; Bridoux J; Hernot S
Curr Opin Chem Biol; 2021 Aug; 63():219-228. PubMed ID: 34325089
[TBL] [Abstract][Full Text] [Related]
2. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
3. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
[TBL] [Abstract][Full Text] [Related]
4. Dual MVK cleavable linkers effectively reduce renal retention of
Valpreda G; Trachsel B; Vogel V; Schibli R; Mu L; Behe M
Bioorg Med Chem; 2022 Nov; 73():117040. PubMed ID: 36202066
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
6. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
Vegt E; de Jong M; Wetzels JF; Masereeuw R; Melis M; Oyen WJ; Gotthardt M; Boerman OC
J Nucl Med; 2010 Jul; 51(7):1049-58. PubMed ID: 20554737
[TBL] [Abstract][Full Text] [Related]
7. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of
Bendre S; Zhang Z; Kuo HT; Rousseau J; Zhang C; Merkens H; Roxin Á; Bénard F; Lin KS
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854201
[TBL] [Abstract][Full Text] [Related]
9. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
[TBL] [Abstract][Full Text] [Related]
10. Preclinical development of small-molecular-weight folate-based radioconjugates: a pharmacological perspective.
Siwowska K; Müller C
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):269-86. PubMed ID: 26149341
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.
Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V
J Nucl Med; 2016 Mar; 57(3):431-6. PubMed ID: 26659353
[TBL] [Abstract][Full Text] [Related]
12.
Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
[TBL] [Abstract][Full Text] [Related]
13. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
14. Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies.
Lau J; Lee H; Rousseau J; Bénard F; Lin KS
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956909
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
Müller C; Farkas R; Borgna F; Schmid RM; Benešová M; Schibli R
Bioconjug Chem; 2017 Sep; 28(9):2372-2383. PubMed ID: 28898054
[TBL] [Abstract][Full Text] [Related]
16. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
17. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer.
Kukis DL; Novak-Hofer I; DeNardo SJ
Cancer Biother Radiopharm; 2001 Dec; 16(6):457-67. PubMed ID: 11789023
[TBL] [Abstract][Full Text] [Related]
18.
Sager S; Aygün A; Karayel E; Pehlivanoğlu H; Sönmezoglu K
J Nucl Med Technol; 2020 Mar; 48(1):79-80. PubMed ID: 31604896
[TBL] [Abstract][Full Text] [Related]
19. Potential Biomarkers for Radiation-Induced Renal Toxicity following 177Lu-Octreotate Administration in Mice.
Schüler E; Larsson M; Parris TZ; Johansson ME; Helou K; Forssell-Aronsson E
PLoS One; 2015; 10(8):e0136204. PubMed ID: 26287527
[TBL] [Abstract][Full Text] [Related]
20. Imaging Bradykinin B1 Receptor with 68Ga-Labeled [des-Arg10]Kallidin Derivatives: Effect of the Linker on Biodistribution and Tumor Uptake.
Amouroux G; Pan J; Jenni S; Zhang C; Zhang Z; Hundal-Jabal N; Colpo N; Liu Z; Bénard F; Lin KS
Mol Pharm; 2015 Aug; 12(8):2879-88. PubMed ID: 26101793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
